Cargando…
Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia
Achondroplasia (ACH) is the most common short-limbed skeletal dysplasia caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3). No effective FGFR3-targeted therapies for ACH are currently available. By drug repositioning strategies, we identified that meclozine, whic...
Autores principales: | Matsushita, Masaki, Esaki, Ryusaku, Mishima, Kenichi, Ishiguro, Naoki, Ohno, Kinji, Kitoh, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547068/ https://www.ncbi.nlm.nih.gov/pubmed/28785080 http://dx.doi.org/10.1038/s41598-017-07044-8 |
Ejemplares similares
-
Meclozine Facilitates Proliferation and Differentiation of Chondrocytes by Attenuating Abnormally Activated FGFR3 Signaling in Achondroplasia
por: Matsushita, Masaki, et al.
Publicado: (2013) -
Meclozine ameliorates bone mineralization and growth plate structure in a mouse model of X‑linked hypophosphatemia
por: Kamiya, Yasunari, et al.
Publicado: (2022) -
Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish
por: Takemoto, Genta, et al.
Publicado: (2022) -
Effect of periosteal resection on longitudinal bone growth in a mouse model of achondroplasia
por: Kaneko, Shinya, et al.
Publicado: (2020) -
Activated FGFR3 suppresses bone regeneration and bone mineralization in an ovariectomized mouse model
por: Kawashima, Itaru, et al.
Publicado: (2023)